GlassScriptPhysician profile
William K Deschner
NPI 1023003563
$9,364.96
in general payments reported to CMS, 2019-2025
40 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $443 · 2021: $1,143 · 2022: $1,383 · 2023: $1,561 · 2024: $2,193 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,355 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,354.63 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,877.17 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $755.65 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $638.31 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $614.16 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.59 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $391.49 | 2019-2025 | |
| Qol Medical, LLC | $343.33 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $250.61 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $237.26 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $228.89 | 2019-2025 | Eohilia, Entyvio |
| Genzyme Corporation | $189.80 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $184.25 | 2021-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $174.09 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $161.86 | 2019-2023 | Rebyota |
| Ardelyx, INC. | $154.62 | 2022-2025 | Ibsrela |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $137.72 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Daiichi Sankyo INC. | $132.25 | 2019-2023 | Injectafer |
| Aimmune Therapeutics, INC. | $128.48 | 2024-2025 | Zenpep |
| Allergan, INC. | $125.90 | 2019 | |
| Amag Pharmaceuticals, INC. | $125.67 | 2021 | |
| Echosens North America, INC. | $112.90 | 2025 | Fibroscan |
| Amgen INC. | $109.46 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $102.64 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $99.47 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $97.52 | 2019-2023 | Linzess |
| Myriad Women'S Health, INC. | $84.97 | 2023 | Myrisk |
| Madrigal Pharmaceuticals | $82.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $60.76 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $60.73 | 2024 | Vegzelma |
| Braintree Laboratories, INC. | $48.22 | 2022-2024 | Suflave, Sutab |
| Evoke Pharma, INC. | $47.60 | 2022-2024 | |
| Ucb, INC. | $33.12 | 2019-2020 | |
| Johnson & Johnson Health Care Systems INC. | $30.84 | 2022-2023 | Stelara |
| Lucid Diagnostics INC. | $24.06 | 2024 | |
| Redhill Biopharma INC. | $20.21 | 2020 | |
| Orphalan INC | $17.07 | 2024 | Cuvrior |
| Micro-Tech Endoscopy USA, INC. | $16.86 | 2020 | |
| Glaxosmithkline, LLC. | $12.78 | 2023 | Arexvy, Shingrix |
| Romark Laboratories, Lc | $10.71 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Deschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.